102 results about "Renal carcinoma" patented technology

The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast Cancer, lung Cancer, gastric Cancer, ovarian Cancer, hepatocellular Cancer, colon Cancer, pancreatic Cancer, esophageal Cancer, head & neck Cancer, kidney Cancer, in particular renal cell Carcinoma, prostate Cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid Cancer, and the metastatic forms thereof. In one embodiment, the rumor disease is metastatic cancer in the lung.

The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin.

The invention relates to an ASPL-TFE3 fused renal carcinoma gene probe as well as an application of a kit thereof. Cloned fragments selected by the gene probe are respectively a combination of RP11-634L10, RP11-51H16 and RP11-475F12 and a combination of CTD-2311N12, RP11-416B14, CTD-2522M13, CTD-2516D6, CTD-2312C1, CTD-2248C21 and RP11-959H17. By using the ASPL-TFE3 fused renal carcinoma gene probe, the defects of complexity, time consumption and clinic application unsuitability of RT-PCR and cell karyotyping methods applied in the past are overcome. According to the ASPL-TFE3 fused renal carcinoma gene probe, a unique ASPL-TFE3 fused gene in ASPL-TFE3 fused renal carcinoma is detected by using an FISH technology, so that the renal carcinoma is diagnosed; the gene probe is high in accuracy rate, specificity and success rate, strong in fluorescence signal, simple and rapid in operation and rapid in diagnosis when applied and can be applied to paraffin section; and due to the application of the ASPL-TFE3 fused renal carcinoma gene probe, the specimen detecting range is widened, a novel method for accurately, reliably, simply and conveniently diagnosing the ASPL-TFE3 fused renal carcinoma is established, and the precedent that the ASPL-TFE3 fused renal carcinoma is detected by virtue of FISH is created.

The invention discloses a usage of Jew ear fungal aqueous extract in the preparation of a drug for curing tumors, wherein, the tumors include cervical cancer, ovarian cancer, carcinoma of endometrium, vulva cancer, prostate cancer, parotid gland, thyroid cancer, salivary gland cancer, skin cancer, nasopharyngeal carcinoma, tongue cancer, oral cavity cancer, carcinoma of larynx, encephaloma, carcinoma of gallbladder, renal carcinoma, gingival carcinoma, testicular cancer, penile cancer, multiple myeloma and / or malignant melanoma.

The invention relates to a method for extracting a clam extract freeze-dried powder. The method is characterized by comprising the following steps: cleaning: fresh marine organism clams are cleaned to remove sludge, shells are removed, soft bodies are taken out and cleaned until no bloodiness is left and then drained, thus obtaining a clean material; mashing: particle size is between 0.2cm and 0.4cm; extracting: the clean material mashed is mixed with water by a ratio of 1:1 to 1:2 in an extraction plant for extraction for 2 hours to 6 hours at temperature between 0 DEG C and 10 DEG C, separation, centrifugation and deslagging are conducted, thus obtaining a centrifugate; and freeze-drying: the clam extract freeze-dried powder is obtained through pre-freezing and first phase and second phase of sublimation. The extraction method is simple and effective, has effective components with the high content of bioactive proteins and is used for producing clam extract enteric-coated capsules to treat early, intermediate stage and terminal cancer patients such as lung cancer, liver cancer, renal carcinoma, carcinoma ventriculi, cervical carcinoma patients and the like.

The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof. In one embodiment, the tumor disease is metastatic cancer in the lung.

The invention discloses a medicinal composition for treating renal carcinoma. The medicinal composition is prepared from the following raw materials in parts by weight: 10-20 parts of desert cistanche, 10-30 parts of eucommia ulmoides, 10-20 parts of ginseng, 10-30 parts of rhizoma atractylodis macrocephalae, 10-20 parts of Chinese angelica, 10-30 parts of astragalus membranaceus, 10-30 parts of smoked plum, 10-30 parts of cynomorium songaricum, 10-20 parts of yam, 10-30 parts of pseudo-ginseng, 10-20 parts of pangolin scales, 10-30 parts of monkshood, 10-20 parts of tortoiseshell, 10-20 parts of turtle shell, 10-20 parts of dragon blood, 10-30 parts of sichuan lovage rhizome, 10-20 parts of salviae miltiorrhizae, 10-30 parts of nightshade, 10-30 parts of Indian strawberry, 10-20 parts of manyleaf paris rhizome, 10-20 parts of donkey-hide gelatin, 10-30 parts of indigo naturalis and 10-30 parts of mercurous chloride. The medicinal composition can be used for effectively treating renal carcinoma diseases and remarkably improving human disease resistance and promoting repairing of renal functions, and has the characteristics of good curative effect and little side effect.

A flaviviral replicon-based construct is provided for delivery and expression of granulocyte-macrophage colony stimulating factor to facilitate tumour therapy. In particular, the replicon construct encodes a Kunjin virus replicon having one or more mutations in an NS2A non-structural protein that induce enhanced levels of cellular IFN that synergize with recombinant granulocyte-macrophage colony stimulating factor delivered according to the invention. The construct may be administered intra-tumourally or peri-tumourally to an animal as DNA, RNA or packaged into a VLP, for the therapeutic and / or prophylactic treatment of tumours and cancers such as melanoma, lung carcinoma, cervical carcinoma, lung epithelial carcinoma, prostate cancer, breast cancer, renal carcinoma, colon cancer, epithelial cancers and mesothelioma.

A semi-synthetic rapamycin analog with a triazole moiety or a pharmaceutically acceptable salt or prodrug thereof, is a broad-spectrum cytostatic agent and a mTOR inhibitor, and is useful in the treatment of various cancers, or tumors in organs such as kidney, liver, breast, head and neck, lung, prostate, and restenosis in coronary arteries, peripheral arteries, and arteries in the brain, immune and autoimmune diseases. Also disclosed are fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosois, post-transplant tissue rejection, and immune and autoimmune disease in a mammal. One particular preferred application of such triazole-moiety containing rapamycin analog is in treating renal carcinoma, lung cancer, colon cancer, and breast cancers wherein potency of the drug, its half-life, tissue distribution properties, and its pharmacokinetic properties including bioavailability through oral and intravenous routes are essential to the clinical outcomes.

The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.

The invention discloses novel Cembrane type diterpenoids with anti-tumor activities. In vitro anti-tumor activity study shows that the Cembrane type diterpenoids have strong anti-tumor activities on a plurality of kinds of tumor cells including gastric cancer, colon cancer, liver cancer or renal carcinoma and the like, and toxicity test study shows that the Cembrane type diterpenoids with anti-tumor activities have low toxicity and can be expected to be developed into novel antitumor drugs.

The invention belongs to the technical field of formulas of medicament for preventing and treating physical diseases and particularly relates to composition capable of preventing and treating respiratory system diseases like novel coronavirus infection and other diseases. Alliin, alliinase and type II transmembrane serine protease inhibitor are taken as basic effective ingredients, the compositionis administered in a way of inhalation by the lung, can kill physical diseases caused by bacteria such as methicillin-resistant staphylococcus aureus, multidrug resistance type escherichia coli, multidrug resistance type pseudomonas aeruginosa, multidrug resistance type mycobacterium tuberculosis and the like, viruses such as SARS-CoV-2 and the like, fungi such as multidrug resistance type candida albicans and the like, parasites and the like in a respiratory system and also can prevent fat accumulation in blood vessels of a human body, reduce the blood pressure, the cholesterol level in blood and destroy cancer cells of multiple epithelial tumors of breast cancer, ovarian cancer, colon cancer, renal carcinoma, liver cancer, lung cancer, mesothelioma and prostatic cancer, and the composition has no any toxic or harmful functions and risks and has broad application prospects.

Aplidine demonstrates considerable promise in phase (I) clinical trials for treatment of tumours, and various dosing regimes are given. Tumor reduction has been observed in several tumour types including renal carcinoma, colorectal cancer, lung carcinoid, medullary thyroid carcinomas and melanoma. It has also been found that aplidine has a role in inhibiting angiogenesis, complementing the anti-tumour activity.

The invention discloses a renal cell carcinoma survival risk biomarker group, a diagnostic product and application, and particularly relates to biomarkers SLC11A1, TEK and THRB. Single factor Cox analysis finds that immune related genes SLC11A1, TEK and THRB are related to survival of renal cell carcinoma, a prediction model is constructed though LASSO Cox analysis, and it is found that the prediction model constructed by the above genes can independently predict prognosis of renal cell carcinoma.